4221 related articles for article (PubMed ID: 26921134)
21. Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography.
Timmers T; van Berckel BNM; Lammertsma AA; Ossenkoppele R
Methods Mol Biol; 2018; 1750():221-229. PubMed ID: 29512076
[TBL] [Abstract][Full Text] [Related]
22. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population.
Bouwman FH; Verwey NA; Klein M; Kok A; Blankenstein MA; Sluimer JD; Barkhof F; van der Flier WM; Scheltens P
Dement Geriatr Cogn Disord; 2010; 30(1):1-7. PubMed ID: 20606438
[TBL] [Abstract][Full Text] [Related]
23. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.
Park JC; Han SH; Yi D; Byun MS; Lee JH; Jang S; Ko K; Jeon SY; Lee YS; Kim YK; Lee DY; Mook-Jung I
Brain; 2019 Mar; 142(3):771-786. PubMed ID: 30668647
[TBL] [Abstract][Full Text] [Related]
24. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
Thal DR; Attems J; Ewers M
J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
[TBL] [Abstract][Full Text] [Related]
25. FDG-PET and amyloid-PET imaging: the diverging paths.
Perani D
Curr Opin Neurol; 2014 Aug; 27(4):405-13. PubMed ID: 24927239
[TBL] [Abstract][Full Text] [Related]
26. Marking the markers of Alzheimer's: too good to diagnose, too bad to use?
Olah Z; Pakaski M; Janka Z; Kalman J
Neuropsychopharmacol Hung; 2012 Sep; 14(3):165-76. PubMed ID: 22987730
[TBL] [Abstract][Full Text] [Related]
27. Why musical memory can be preserved in advanced Alzheimer's disease.
Jacobsen JH; Stelzer J; Fritz TH; Chételat G; La Joie R; Turner R
Brain; 2015 Aug; 138(Pt 8):2438-50. PubMed ID: 26041611
[TBL] [Abstract][Full Text] [Related]
28. Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.
Smith R; Wibom M; Olsson T; Hägerström D; Jögi J; Rabinovici GD; Hansson O
J Alzheimers Dis; 2016; 51(2):339-43. PubMed ID: 26836192
[TBL] [Abstract][Full Text] [Related]
29. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
30. Dissecting molecular mechanisms in the living brain of dementia patients.
Barrio JR; Satyamurthy N; Huang SC; Petric A; Small GW; Kepe V
Acc Chem Res; 2009 Jul; 42(7):842-50. PubMed ID: 19281227
[TBL] [Abstract][Full Text] [Related]
31. Which Episodic Memory Performance is Associated with Alzheimer's Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD).
Gagliardi G; Epelbaum S; Houot M; Bakardjian H; Boukadida L; Revillon M; Dubois B; Dalla Barba G; La Corte V;
J Alzheimers Dis; 2019; 70(3):811-824. PubMed ID: 31282413
[TBL] [Abstract][Full Text] [Related]
32. Are the brain's vascular and Alzheimer pathologies additive or interactive?
Koncz R; Sachdev PS
Curr Opin Psychiatry; 2018 Mar; 31(2):147-152. PubMed ID: 29232251
[TBL] [Abstract][Full Text] [Related]
33. In-vivo brain neuroimaging provides a gateway for integrating biological and clinical biomarkers of Alzheimer's disease.
Cui J; Zufferey V; Kherif F
Curr Opin Neurol; 2015 Aug; 28(4):351-7. PubMed ID: 26132531
[TBL] [Abstract][Full Text] [Related]
34. [Molecular imaging of Alzheimer's disease].
Albert A; Borbély K
Orv Hetil; 2019 Aug; 160(33):1289-1295. PubMed ID: 31401858
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers reflecting different facets of Alzheimer's disease.
Zetterberg H
Eur J Neurol; 2008 Nov; 15(11):1143-4. PubMed ID: 18973609
[No Abstract] [Full Text] [Related]
36. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
[TBL] [Abstract][Full Text] [Related]
37. Alzheimer's disease neuroimaging.
Whitwell JL
Curr Opin Neurol; 2018 Aug; 31(4):396-404. PubMed ID: 29762152
[TBL] [Abstract][Full Text] [Related]
38. [Biological markers in the diagnosis of dementia and Alzheimer's disease].
Meiner Z; Rosenmann H
Harefuah; 2012 May; 151(5):289-93, 318. PubMed ID: 22844733
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic value of FDG and amyloid PET in Alzheimer's disease-A systematic review.
Rice L; Bisdas S
Eur J Radiol; 2017 Sep; 94():16-24. PubMed ID: 28941755
[TBL] [Abstract][Full Text] [Related]
40. Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β.
Maya Y; Okumura Y; Kobayashi R; Onishi T; Shoyama Y; Barret O; Alagille D; Jennings D; Marek K; Seibyl J; Tamagnan G; Tanaka A; Shirakami Y
Brain; 2016 Jan; 139(Pt 1):193-203. PubMed ID: 26490333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
